Endoglin/CD 105 may not be an optimal tumor endothelial treatment target.
Griffioen
A W
AW
Damen
C A
CA
Blijham
G H
GH
Groenewegen
G
G
D000818:Animals; D015703:Antigens, CD; D002292:Carcinoma, Renal Cell / Q000098:blood supply* / Q000188:drug therapy; D000071063:Endoglin; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000276:immunology; D005260:Female; D006801:Humans; D000922:Immunotoxins / Q000494:pharmacology; D007680:Kidney Neoplasms / Q000098:blood supply* / Q000188:drug therapy; D051379:Mice; D011956:Receptors, Cell Surface; D019010:Vascular Cell Adhesion Molecule-1 / Q000009:adverse effects / Q000096:biosynthesis / Q000627:therapeutic use*
D015703:Antigens, CD; C064206:ENG protein, human; D000071063:Endoglin; D000922:Immunotoxins; D011956:Receptors, Cell Surface; D019010:Vascular Cell Adhesion Molecule-1